PTX thus far...,

Inspired by Philley, a quick summary for current and prospective holders alike.

4 concurrent clinic trials, 2 compounds : Phase 2 (P2) Breastcancer (ptx200), AML (P1), Ovarian cancer (P1) and multiple cancers ‘basket trial’ (P1) (ptx100).

2 out-licensed compounds via the co-x-gene technology to Transgene.
TG4010 and TG4001 (upon commercialisation 11mil royalties).

PTX200
Breast cancer study;
Standout results (best in class) for P1 (n<15.., small population). Durability factor in complete response (CR) > 36 months ( 5 years is seen as optimal in this area). Currently in P2, readout Q4 2019.

AML study; ( orphan status granted)
Currently in P1 extended arm combined therapy with 50% reduction to the chemotherapy component.
Outstanding results as a monotherapy, PR > 50% (partial response). Readout Q4 2019.

Ovarian study;
as above, in combined therapy with 50% reduction to the chemotherapy component. No published results thus far. Readout Q3 2019.

PTX100:
Multiple cancer ‘basket trial’ study. Readout Q2 2020.
As our CEO stated, possible one of very few compounds to qualify for a Basket case study.

MC ( market cap) ~20mil
Cash ~10mil
Burn rate~2.5mil
EV (enterprise value)~10mil
Registry ~400mil

Like many LT holders, I share the disappointment of the company’s recent dilution as evident by the paper losses. Yet, continue to accumulate and average down.
To new and prospective holders, possibly a great entry point with a word of caution of course.
IMO, remembering, PTX ( like any other penny stock) is still a spec stock ( ongoing CR’s and not yet licensed let alone commercialised).
As a last note, illustration only and not cross promoting, I currently hold a penny stock ASX biotech that it’s EV is 10 times it’s current cash value. Of course, it does have a de-risking component of a option to license yet not upfront payment nor any monetary current value agreed.
That said, all the best to all holders and volunteers on our trials alike.